• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • T Regulatory Cell Therapies
      • SOD1 Therapies & Trials
    • Approved Drugs
      • Neudexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day Calendar
    • March of Faces
    • Patient Fellows Program
    • International Symposium
  • About
    • Who We Are
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Student Innovation Award
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
  • Members
    • Member Registration
    • Forgot Password

Join the Alliance

The International Alliance of ALS/MND Associations encourages all organisations involved in support of people living with ALS/MND, and other organisations with an interest in ALS/MND, to apply for membership of the Alliance.

We have three levels of membership: Full, Affiliate, and Honorary. See below for criteria, application requirements, and fees for each membership level.

Membership Criteria, Application Requirements & Fees

Full Membership

The criteria for Full Membership in the Alliance will be Organisations which:

  • Serve people with ALS/MND or related disorders with a focus on patient advocacy;
  • Are chartered in own country as a non-profit national or independent organisation for at least 2 years;
  • Have a legal constitution or by-laws;
  • Are governed by a volunteer Board of Directors (however described), elected by and/or from the membership which includes people living with ALS/MND, carers, past carers, or people closely associated with the disease;
  • Prepare an annual financial statement; and,
  • Sign and fulfill the Alliance Code of Conduct

Prospective members must submit a cover letter stating their reasons for wanting to become a member of the International Alliance, which must be accompanied by the specified information below.

Applicants for Full Membership must submit the following documents in English:

  • Cover letter
  • Proof of non-profit status in their country
  • Copy of their constitution and/or by-laws
  • List of names of the Board of Directors (however described) and Officers
  • Mission or purpose statement (most likely in constitution)
  • Written financial statement of previous year’s income
  • Copies of brochures and other materials (if not in English, then with some English translation)

The fee for Full Membership is either an amount equal to 0.2% of total annual income of the applicant organisation or £UK100, which ever is greater. At the discretion of the Board of Directors, fees can be waived or reduced for members that demonstrate need and make a request in writing.

Affiliate Membership

The criteria for Affiliate Membership in the Alliance will be Organisations which:

  • Serve people with ALS/MND or related disorders with a focus on patient advocacy;
  • Are chartered in own country as a non-profit national or independent organisation (or status pending) by July 1st of the current membership year;
  • Have a legal constitution or by-laws;
  • Are governed by a volunteer Board of Directors (however described), elected by and/or from the membership which includes people living with ALS/MND, carers, past carers, or people closely associated with the disease;
  • Prepare an annual financial statement; and,
  • Sign and fulfill the Alliance Code of Conduct

Prospective members must submit a cover letter stating their reasons for wanting to become a member of the International Alliance, which must be accompanied by the specified information below.

Applicants for Affiliate Membership must submit the following documents in English:

  • Cover letter
  • Proof of non-profit status in their country
  • Copy of their constitution and/or by-laws
  • List of names of the Board of Directors (however described) and Officers
  • Mission or purpose statement (most likely in constitution)
  • Written financial statement of previous year’s income
  • Copies of brochures and other materials (if not in English, then with some English translation)

Subscriptions are £100 (pounds sterling).

Honorary Membership

Honourary membership may be conferred on key contributors to the Alliance at the discretion of the Board of Directors for service rendered in achieving the vison of the Alliance: A World Free of ALS/MND! These key contributors can be former Board Members, Patrons, Staff or Award winners.

 

For any questions or for further information, please contact the Executive Director at alliance@als-mnd.org.

The Board of Directors of the Alliance will review applications and supporting documentation received. Decisions are made at the Board of Directors Meetings, which are held quarterly. An email will be forwarded advising applicants of the Board’s decision.

Participation at the Alliance Meeting is encouraged for prospective new members. Observer status will be granted.

Primary Sidebar

  • Mike Small, Motor Neurone Disease (MND) Association, UK

    Mike Small, Motor Neurone Disease (MND) Association, UK

  • Zelina Brito, Diagnosed 2018, Brazil

    Zelina Brito, Diagnosed 2018, Brazil

  • Maurice Leclerc, Canada

    Maurice Leclerc, Canada

  • Oliver Juenke, DGM, Germany

    Oliver Juenke, DGM, Germany

  • Ann Nicol

    Ann Nicol

  • Ali Var, Turkey

    Ali Var, Turkey

  • João Marcos Andrietta, Diagnosed 2008 , ABrELA, Brazil

    João Marcos Andrietta, Diagnosed 2008 , ABrELA, Brazil

  • Jon Newsome, USA

    Jon Newsome, USA

  • Jack Buzby, USA

    Jack Buzby, USA

  • Shay Rishoni, Diagnosed 2011 , Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 , Prize4Life, Israel

  • Alfredo Santos, Diagnosed 2013 , ACELA, Colombia

    Alfredo Santos, Diagnosed 2013 , ACELA, Colombia

  • Susan Keldani, Les Turner ALS Foundation, USA

    Susan Keldani, Les Turner ALS Foundation, USA

  • Mike Rannie,  ALS Canada,  Diagnosed 2017

    Mike Rannie, ALS Canada, Diagnosed 2017

  • Glen Elison,  ALS Hope Foundation,  Diagnosed 2019,  USA

    Glen Elison, ALS Hope Foundation, Diagnosed 2019, USA

  • Bruno Leanza Mantegna, Diagnosed 1999 , AISLA Onlus, Italy

    Bruno Leanza Mantegna, Diagnosed 1999 , AISLA Onlus, Italy

  • Kirsten Harley,  Diagnosed 2013,  Australia

    Kirsten Harley, Diagnosed 2013, Australia

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • unnamed

    unnamed

  • Lachlan Terry,  MND Australia,  Diagnosed 2015

    Lachlan Terry, MND Australia, Diagnosed 2015

  • Feng Gin Sun, Diagnosed 2014 , Shaanxi ALS Association, China

    Feng Gin Sun, Diagnosed 2014 , Shaanxi ALS Association, China

  • Maria Lucia Wood Saldanha, Associação Pró-Cura da ELA, Brazil

    Maria Lucia Wood Saldanha, Associação Pró-Cura da ELA, Brazil

  • Dad

    Dad

  • Joanne Pratt, Diagnosed 2011 , MND Australia

    Joanne Pratt, Diagnosed 2011 , MND Australia

  • Orlando Ruiz, Diagnosed 2001,  ACELA, Colombia

    Orlando Ruiz, Diagnosed 2001, ACELA, Colombia

  • Malcolm Buck, Australia

    Malcolm Buck, Australia

  • Philip Brindle,  MND Association,  Diagnosed 2015,  England

    Philip Brindle, MND Association, Diagnosed 2015, England

  • Monica Soriano, Diagnosed 2011 ,  Asociación ELA , Argentina

    Monica Soriano, Diagnosed 2011 , Asociación ELA , Argentina

  • Jorge Melo, ABrELA, Brazil

    Jorge Melo, ABrELA, Brazil

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Christian Bär, Germany

    Christian Bär, Germany

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Brian Parsons

    Brian Parsons

  • Sébastien Batiot, Diagnosed 2012 , ARSLA, France

    Sébastien Batiot, Diagnosed 2012 , ARSLA, France

  • Lucy Lintott, Diagnosed 2013 , MND Scotland, UK

    Lucy Lintott, Diagnosed 2013 , MND Scotland, UK

  • Ian Gale, MND Australia

    Ian Gale, MND Australia

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Timothy Holman, Switzerland

    Timothy Holman, Switzerland

  • Daniel Hare

    Daniel Hare

  • Karl Hughes, Diagnosed 2010 , IMNDA,  Ireland

    Karl Hughes, Diagnosed 2010 , IMNDA, Ireland

  • England-Lee-Millard, UK

    England-Lee-Millard, UK

  • Charlie “Hark” Dourney, Diagnosed 2007 , Hark ALS, USA

    Charlie “Hark” Dourney, Diagnosed 2007 , Hark ALS, USA

  • Dorette Lüdi, Diagnosed 2014 , ALS Schweiz, Switzerland

    Dorette Lüdi, Diagnosed 2014 , ALS Schweiz, Switzerland

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Leon Ryba, Asociación ELA Argentina

    Leon Ryba, Asociación ELA Argentina

  • Dawn Morton, Diagnosed 2014 , MND Scotland, UK

    Dawn Morton, Diagnosed 2014 , MND Scotland, UK

  • Andrea Zicchieri, Associazione conSLAncio Onlus, Italy

    Andrea Zicchieri, Associazione conSLAncio Onlus, Italy
    AndreaZicchieri_conSLAncioItaly

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • John Dinon, MND Australia

    John Dinon, MND Australia

  • Sally Pauls, Diagnosed 2006 , Les Turner ALS Foundation

    Sally Pauls, Diagnosed 2006 , Les Turner ALS Foundation

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login